Eton Pharmaceuticals, Inc. ETON

Updated: 10 Aug 2026

NASDAQ | Biotech | Rare disease pharmaceuticals

No signal published yet

We already track Eton Pharmaceuticals and collect the news. No signal is published yet — follow the company free and we will email you when that changes, or run a quick check now.

Follow Eton Pharmaceuticals free Follow free

Email when we publish a signal or something material happens · Sunday weekly brief

No card · No time limit on free tier · Upgrade when you need more

Free
No email, no account, no signup.
Exchange
NASDAQ
Type
Biotech
Sector
Rare disease pharmaceuticals
We're already tracking Eton Pharmaceuticals, Inc. — here are the latest events we've registered

Recent News

  • On August 5, 2026, Eton Pharmaceuticals announced it had acquired exclusive U.S. rights to product candidate ASN-001 from Auson Pharmaceuticals for the treatment of infantile hemangiomas. The company plans to conduct a bioavailability bridging study before submitting a New Drug Application in the second half of 2027.

What Firelda Watch includes for Eton Pharmaceuticals, Inc.

Add the company to your watchlist and get all of this automatically.

  • Free: 3 companies on your watchlist
  • Change history and monitoring for every company you follow
  • Sunday weekly brief — a short weekly roundup
  • Watch/Ultra: same-day email when something material happens
Want to see what a finished analysis looks like?
View a sample analysis
This is a real Firelda analysis. Your analysis of Eton Pharmaceuticals, Inc. will be delivered in the same format.

Want to follow Eton Pharmaceuticals, Inc.? Create a free account — 3 companies, change history, weekly brief, and email when the picture changes.

Follow Eton Pharmaceuticals free Follow free

Email when we publish a signal or something material happens · Sunday weekly brief

No card · No time limit on free tier · Upgrade when you need more

Eton Pharmaceuticals, Inc. ETON
Eton Pharmaceuticals — follow and we'll monitor it
Follow Eton Pharmaceuticals free Follow free
Firelda provides general information and analysis, not personal investment advice. Content does not consider your financial situation or goals. Investments can rise and fall in value. Always do your own research.